Medical network - February 3, time flies, suddenly we ushered in the New Year, everyone began to the pharmaceutical industry has a new look forward to the new development.
In recent years, for the pharmaceutical listed companies on the Chinese capital market, is expected to rise and fall, like a roller coaster of a year, the driving force of capital directly determines the domestic medicine companies eventually on the market value of listed companies rankings.
And pharmaceutical sector is no stranger to a lot of people say, when markets are in a vulnerable period, this section can always bring us some surprises, especially can easily become weak market bulk varieties. Even met the market volatility, pharmaceutical stocks or attention, is relatively stable demand for drugs and medical services, and for the physical laws of nature, is unable to avoid drugs has become an indispensable product.
In the past two years, a new version of GMP, the full implementation of the new GSP, fly check storm hits, the new "pharmacopoeia" fully implementing, large clinical trials for verification, the tax system upgrade, the tender annual crazy prices, the greater the medicine circulation spirit scrutiny... This makes many medicine enterprises overwhelmed. But even in such a policy environment, many companies can still walk the line, get high grades.
The blue parker according to flush data, statistical draw as of December 31, 2016, 171 Chinese medicine and the market value of listed companies. Among them, the market capitalisation of more than 10 billion yuan, a total of 85.
It is worth mentioning that Shanghai to alex's $113.716 billion market value of the top again, hengrui pharmaceutical value also breakthrough billions, reaching 106.809 billion yuan. The two drug firms is also currently the only value of drug firms squeeze into billions of market force.
Add: 2016 Chinese listed companies list
